Wockhardt Limited
WOCKPHARMA
주식 순위
#4516
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
주가
$21.04
마지막 동기화: 2026-10-19
시가총액
$3.42B
변동 (1일)
-2.39%
변동 (1년)
34.90%
국가
IN
거래 Wockhardt Limited (WOCKPHARMA)
카테고리
Healthcare
Wockhardt Limited (WOCKPHARMA)의 발행 주식 수
June 2026 기준 발행 주식 수: 162.49M
Wockhardt Limited의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 162.49M입니다. March 2024 말 기준 회사는 144.25M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
Wockhardt Limited (WOCKPHARMA)의 발행 주식 수 기록 (2004 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2026 (TTM) | 162.49M | 4.41% |
| 2025 | 155.63M | 7.89% |
| 2024 | 144.25M | 0.13% |
| 2023 | 144.06M | 19.50% |
| 2022 | 120.55M | 0.31% |
| 2021 | 120.19M | 0.03% |
| 2020 | 120.15M | 0.05% |
| 2019 | 120.09M | 8.60% |
| 2018 | 110.58M | 0.06% |
| 2017 | 110.51M | -0.60% |
| 2016 | 111.18M | -0.08% |
| 2015 | 111.27M | 0.20% |
| 2014 | 111.04M | -0.15% |
| 2013 | 111.21M | -6.35% |
| 2012 | 118.76M | 0.00% |
| 2011 | 118.76M | 0.00% |
| 2010 | 118.76M | 0.00% |
| 2008 | 118.76M | 0.00% |
| 2007 | 118.76M | 0.02% |
| 2006 | 118.74M | 0.24% |
| 2005 | 118.46M | 0.00% |
| 2004 | 118.46M | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| 445.06M | 173.90% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 105.38M | -35.15% |
US
|
